All In Biotech

Drug Trial Radar · NCT05434312

TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients

A Single-arm, Open-label, Dose Escalation and Dose Expansion Phase 1 Trial to Determine the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-678 in Patients With Refractory or Advanced CML

Last checked: Nov 19, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Mar 29, 2021

Primary completion

Mar 2026

Study completion Sep 2026

Sponsor

Lead sponsor
Shenzhen TargetRx Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Peking University People's Hospital
First posted
Jun 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this single- arm, open-lable, dose escalation + dose expansion study is to evalulate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.

Conditions

  • Chronic Myelogenous Leukemia

Interventions

  • TGRX-678Drug

    Participants are given TGRX-678 tablets orally at one of the dose levels as pre-determined for the dose escalation sequence.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximal tolerated dose (MTD)Time frame: At end of Cycle 1 (each cycle is 28 days) when the posterior probability of DLT of a dose level is higher than 33%
  2. Recommended phase II dose (RP2D)Time frame: At completion of the study, an average of 1.5 years
  3. Safety profile (DLT)Time frame: DLT: collect during Cycle 1 (28 days)
  4. Safety profile (AEs/SAEs)Time frame: AE and SAE: through completion of the study, an average of 1.5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.